bluebird bio Inc Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US Investor Call Transcript
Good morning, and thank you for standing by. Welcome to the bluebird bio conference call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Courtney O'Leary, Investor Relations. Please go ahead.
' -
Good morning, everyone, and thank you for joining today's call to discuss this morning's restructuring announcement. The press release announcing these updates can be found on the Investor Relations section of our website.
Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including our statements regarding potential cost savings from our restructuring and the expected impacts on our operating expenses and cash runway.
Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |